Skip to content

Released Mar 2, 2020, after the close

10-K filed Mar 2, 2020, 62 days after period end · 0001564590-20-008141

Q4 2019 · 10-K
Revenue$2.80M+68.7% vs Q4 2018+15.4% vs Q3 2019
Net Income-$28.30MN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.37N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$29,078,000N/M
Operating Cash Flowderived-$25,535,000N/M
Free Cash Flowderived-$28,125,000N/M
Margins · derived
Operating margin-1037.8%−29.9 pt vs Q4 2018
Net margin-1010.1%−45.2 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017Q4 2016
Revenue$2.80M$1.66M$1.03M$1.03M
Net Income-$28.30M-$16.03M-$12.50M-$7.94M
EPS Diluted-$0.37-$0.25-$0.29-$0.21

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR